Clinical data | |
---|---|
Trade names | Renormax |
AHFS/Drugs.com | International Drug Names |
Pregnancy category |
|
Routes of administration | Oral |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | 50% |
Metabolism | converted to spiraprilat |
Elimination half-life | 30 to 35 hours |
Excretion | Hepatic and renal |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C22H30N2O5S2 |
Molar mass | 466.61 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Spirapril, sold under the brand name Renormax among others, is an ACE inhibitor antihypertensive drug used to treat hypertension. It belongs to dicarboxy group of ACE inhibitors.[citation needed]
It was patented in 1980 and approved for medical use in 1995.[1]